Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Phase II results of psoriasis drug presented at dermatology meeting
June 6th, 2005
Astralis, Ltd., (ASTR) announced that the results of its 120-patient, 11-site, multidose phase II clinical trial of Psoraxine, its product for the treatment of psoriasis, was presented at the Society of Investigational Dermatology meeting in St. Louis, Missouri, on May 6, 2005. The report authored by James Kreuger, professor and medical director of Investigative Dermatology at Rockefeller University, and Bruce Miller, MD at Oregon Medical Research Center, presents both PASI (Psoriasis Area Severity Index) and patient biopsy results, respectively the primary and secondary endpoints of the trial. Although the six injection, 20 week trial of Psoraxine...
Source: Biotech Business Week (2005-06-06)
|
